SBRT Safe, Effective for Intermediate-Risk Prostate Cancer -

The phase 3 PACE-B trial demonstrated that stereotactic body radiation therapy is noninferior to conventional radiation therapy for low- and favorable-intermediate-risk prostate cancer with respect to biochemical clinical failure. Stereotactic body radiation therapy is noninferior to conventional external beam radiation therapy for low- and favorable-intermediate-risk prostate cancer.

Related Keywords

United Kingdom , London , City Of , Vermont , United States , Canada , San Diego , California , Burlington , Amaru Kishan , Natanielh Lester Coll , , American Society For Radiation Oncology , David Geffen School Of Medicine , Department Of Radiation Oncology , University Of Vermont Medical Center , Genitourinary Oncology Services , American Society , Radiation Oncology , Prostate Advances , Comparative Evidence , Medical Director , Royal Marsden , David Geffen School , Vermont Medical Center ,